Industry Trend Analysis – Novo Nordisk R&D Trimming Highlights De …

Industry Trend Analysis – Novo Nordisk R&D Trimming Highlights De …

BMI View: Novo Nordisk's discontinuation of its anti-inflammatory programmes is part of a trend within multinational pharmaceutical companies of de-diversification and narrowing business focus. With increased competition from Eli Lilly and Sanofi in

(Visited 1 times, 1 visits today)
4
Like
Save

Comments

Comments are disabled for this post.